Phase 2 Trial of GV20-0251 With Anti-PD-1 Therapy in mCRPC
GV20-0251 is an experimental antibody that blocks a new immune brake called IGSF8, and this phase 2 study tests it together with anti-PD-1 drugs in people with advanced solid tumors that no longer respond to standard treatment. The goal is to restore early innate immune signaling so checkpoint therapy works better in resistant cancers. From […]
